CalciMedica (NASDAQ:CALC) Announces Earnings Results

CalciMedica (NASDAQ:CALC) issued its quarterly earnings data on Tuesday. The company reported ($0.69) earnings per share for the quarter, FiscalAI reports.

CalciMedica Trading Up 14.4%

CALC opened at $0.58 on Wednesday. The company has a market cap of $8.36 million, a P/E ratio of -0.36 and a beta of 0.60. The company has a current ratio of 4.03, a quick ratio of 4.04 and a debt-to-equity ratio of 1.39. The company’s 50 day moving average is $3.20 and its 200-day moving average is $3.38. CalciMedica has a 1-year low of $0.46 and a 1-year high of $7.20.

Institutional Trading of CalciMedica

Hedge funds have recently added to or reduced their stakes in the stock. Sound View Wealth Advisors Group LLC acquired a new position in shares of CalciMedica during the second quarter worth $32,000. Cetera Investment Advisers grew its position in CalciMedica by 33.1% during the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock worth $58,000 after acquiring an additional 9,045 shares during the last quarter. Atria Investments Inc increased its holdings in CalciMedica by 20.0% in the 2nd quarter. Atria Investments Inc now owns 44,700 shares of the company’s stock worth $72,000 after purchasing an additional 7,436 shares in the last quarter. Jane Street Group LLC acquired a new position in CalciMedica in the 4th quarter worth about $127,000. Finally, Envestnet Asset Management Inc. raised its position in CalciMedica by 58.2% in the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after purchasing an additional 34,386 shares during the last quarter.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on CALC. HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a research note on Thursday, January 29th. Wall Street Zen raised CalciMedica to a “sell” rating in a report on Saturday, January 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of CalciMedica in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $16.00.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.